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Objective: Considering that global left ventricular systolic radial strain is a sensitive technique 
for the early detection of left ventricular dysfunction due to antineoplastics and the analysis 
of segmental myocardial contractility, we evaluated this technique for early detection of 
trastuzumab-related cardiotoxicity by comparing it with cardiac structural damage.
Methods: Groups of six mice were injected with trastuzumab or doxorubicin, used 
either as single agents or in combination. Cardiac function was evaluated by transthoracic 
echocardiography measurements before and after treatment for 2 or 7 days, by using a Vevo 
2100 high-resolution imaging system. After echocardiography, mice were euthanized, and 
hearts were processed for histological evaluations, such as cardiac fibrosis, apoptosis, capillary 
density, and inflammatory response.
Results: Trastuzumab-related cardiotoxicity was detected early by 2D strain imaging. Radial 
strain was reduced after 2 days in mice treated with trastuzumab alone (21.2%±8.0% vs 
40.5%±4.8% sham; P,0.01). Similarly, trastuzumab was found to induce apoptosis, capillary 
density reduction, and inflammatory response in cardiac tissue after 2 days of treatment, in a 
fashion similar to doxorubicin. On the contrary, fractional shortening reduction and cardiac 
fibrosis were observed only after 7 days of trastuzumab treatment, in contrast to doxorubicin 
treatment which induced early fibrosis and fractional shortening reduction.
Conclusion: The reduction of left ventricular systolic strain after 2 days of trastuzumab treat-
ment may indicate early myocardial functional damage before the reduction in left ventricular 
ejection fraction and this early dysfunction is well correlated with structural myocardial damage, 
such as apoptosis and inflammatory response. Fractional shortening reduction after 7 days of 
trastuzumab treatment is related to fibrosis in cardiac tissue.
Keywords: trastuzumab, breast cancer, cardiotoxicity, ErbB2/Her2, doxorubicin
Introduction
The overall survival of cancer patients has been increased by novel therapeutic 
regimens and the introduction of biological drugs. As a paradox in cancer survivors, 
cardiotoxicity has emerged as important issue.1
Anthracyclines are effective antineoplastic agents in cancer treatment but their clinical 
use is compromised by the development of a severe form of cardiomyopathy and heart 
failure (HF).2,3 Doxorubicin represents the most effective anthracycline, and the mecha-
nisms of doxorubicin-related cardiac toxicity have been extensively studied. Two main 
pathways have been proposed; first, doxorubicin induces cardiotoxicity by reactive oxygen 
species formation;4 second, doxorubicin-top2β complex in cardiomyocytes plays a key role 
to induce changes in mitochondrial membrane potential, function, and morphology.5
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However, also biological agents, such as tyrosine kinase 
inhibitors and monoclonal antibodies (mAbs) developed 
to target specific growth signaling pathways,6 surprisingly 
present important side effects due to both “on target” and 
“off target” activities,7 and they can both be associated with 
severe cardiovascular toxicity.8
The cardiotoxicity of anti-ErbB2 antibodies has been 
initially evidenced for trastuzumab, a humanized anti-ErbB2 
monoclonal antibody.9 Clinical studies demonstrated that 
adjuvant trastuzumab administered either after, or in com-
bination with, chemotherapy reduced the risk of relapse by 
approximately 50% and the risk of death by 33% for women 
with HER-2 positive early breast cancer.10 However, cardiac 
toxicity emerged as an important side effect at an early stage 
in the development of trastuzumab, manifested as symptom-
atic congestive HF or asymptomatic left ventricular ejection 
fraction (LVEF) decline11 that in some cases can cause severe 
cardiac insufficiency and even death.12 Trastuzumab-related 
cardiotoxicity is due to the inhibition of ErbB4/ErbB2 
heterodimerization,13 thus leading to the blockage of the NRG 
activated cardiomyocyte survival pathway.14
Initially, two categories of cancer therapy-related car-
diotoxicity have been proposed by Ewer and Ewer: Type I 
and Type II cardiotoxicity. Type I cardiotoxicity, defined as 
permanent cardiotoxicity, is usually associated with anthra-
cyclines. Type II cardiotoxicity, considered as reversible 
cardiotoxicity, not associated with histologic alteration, has 
been mainly related to trastuzumab and other targeted cancer 
therapy.15 Guarnieri et al16 reported that in three patients 
who experienced a cardiac event (defined by Seidman et al’s 
criteria)17 there was no evidence of structural damage on light 
microscopy analysis; however, an additional ultrastructural 
evaluation showed evidence of focal vacuolar changes, 
pleomorphic mitochondria, myocardial cell hypertrophy, 
and mild interstitial fibrosis. Anyway, the authors still 
consider these ultrastructural changes as a reversible type 
of cardiomyopathy.16 Although the number of patients was 
small and light microscopy is not sensitive enough to detect 
myocardial damage.
Recently, the cardiotoxic side effects of trastuzumab have 
been reconsidered,18,19 as they can persist many years after the 
conclusion of the therapy or they can appear many years after the 
treatment as it takes a long time for the initial heart damage to 
become clinically evident as HF,18 thus strongly suggesting that 
they are not always reversible as it was initially proposed.
Early detection of this phenomenon could allow for the 
reversal of this natural progression through an appropriate 
pharmacological intervention and reconsideration of treatment 
regimens in oncology. Currently, the two-dimensional 
echocardiographic assessment of left ventricular (LV) func-
tion by calculating the ejection fraction (EF) is the most com-
monly used methodology in clinical practice for the study of 
systolic function in patients undergoing antineoplastic treat-
ment. However, this technique, which measures the global 
myocardial function, has limitations both in the evaluation 
of segmental myocardial changes20 and in the early detection 
of myocardial damage by antineoplastic agents. 
The recent development of myocardial strain imaging 
provides a sensitive and reproducible measurement of LV 
systolic function. 
Plana et al,21 in their proposed guidelines, indicated that 
myocardial deformation can be measured by using Doppler 
tissue imaging (DTI) or 2D Speckle tracking echocardiog-
raphy (STE). 2D STE is preferable because it lacks angle 
dependency. Moreover, Global longitudinal strain (GLS) 
represents an optimal parameter of deformation for early 
detection of subclinical LV dysfunction.
The purpose of this study is to compare the alterations 
of LVEF and LV systolic strain measured with 2D strain 
imaging after cancer treatment with doxorubicin and the anti-
ErbB2 agent trastuzumab in a mouse model, and to correlate 
these with histological damage. Global LV systolic radial 
strain (RS) is a sensitive technique for the early detection 
of LV dysfunction from antineoplastics, and completes the 
information obtained with indices of global function. Indeed 
we have shown that there is a clear correlation between early 
detection through global LV systolic RS and myocardium 
damage in trastuzumab-treated mice.
Materials and methods 
animal studies
Seventy two six to eight-week-old female C57Bl/6 mice were 
purchased by Harlan, San Pietro al Natisone, (Italy). Mice 
were housed 6 per cage and maintained on a 12 h light: 12 h 
dark cycle (lights on at 7.00 am) in a temperature-controlled 
room (22±2°C) and with food and water ad libitum at all 
times. The experimental protocols were in accordance with 
EU Directive 2010/63/EU for animal experiments, and 
institutional guidelines of the Italian Ministry of Health 
Animal Care and Use Committee all animal experiments 
were approved by the local ethics committees Organismo 
preposto al benessere degli animali (OPBA).
After 1 week, mice were randomized for weight. All mice 
were enrolled in treatment groups: Ctr treated with 100 µl di 
Saline solution, Doxorubicin 2.17 mg/Kg/day as a positive 
control, Trastuzumab 2.25 mg/Kg/day (Genentech, South San 
Francisco, CA, USA), and Doxorubicin plus Trastuzumab 
via intraperitoneal.
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Transthoracic echocardiography
In vivo cardiac function was assessed by transthoracic 
echocardiography in sedated mice by using a Vevo 2100 
high-resolution imaging system (40-MHz transducer; 
Visualsonics, Toronto, ON, Canada). Mice were anesthetized 
with tiletamine (0.09 mg/g), zolazepam (0.09 mg/g), and 
0.01% atropine (0.04 mL/g). Cardiac function was evaluated 
by noninvasive echocardiography in basal conditions and 
after treatment (T0-T2-T7) with doxorubicin, trastuzumab, 
and doxorubicin plus trastuzumab. The LV echocardiogram 
(ECG) was assessed in both parasternal long-axis and short-
axis views at a frame rate of 233 Hz. End-systole and end-
diastole dimensions were defined as the phases corresponding 
to the ECG T wave, and to the R wave, respectively. M-mode 
LV end-systolic dimensions (LVESDs) and LV end-diastolic 
dimensions (LVEDDs) were averaged from 3 to 5 beats. 
LVEDD and LVESD were measured from the LV M-mode 
at the mid-papillary muscle level. Fractional shortening 
percentage (%FS) was calculated as:
(LVEDD-LVESD)/LVEDD) ×100.22
RS was evaluated by 2D speckle tracking echocardiog-
raphy; pictures were captured with a frame rate between 
50 e 70 frames/sec and three cardiac cycles were analysed. 
For strain analysis, endocardial border was traced manually 
and the myocardial region of interest was automatically 
identified by the Vevo strain. The curves were analyzed after 
the selection of the region of interest. The evalu ations were 
performed on the six segments of the short-axis projection 
standard. Means were calculated automatically by Vevo 
strain software.
Cardiac fibrosis analysis
For ex vivo analyses, animals were euthanized after the treat-
ment by cervical dislocation following anesthesia performed 
as described earlier, the hearts were excised and fixed in 10% 
neutral buffered solution.
The myocardial tissue was formalin-fixed and paraffin- 
embedded for morphometry and immunohistochemistry. 
General morphology was studied with hematoxylin–eosin 
staining. Six µm thick cross sections were deparaffinized and 
stained with Picrosirius red (Carlo Erba Laboratories, Milan, 
Italy) to measure the collagen content. Collagen volume frac-
tion was expressed as the mean percentage of Picrosirius red 
stained tissue areas divided by total tissue area in the same 
field and was evaluated in 15 fields at 60× magnification.23 
The positively stained (red) fibrotic area was measured by 
using a computer-assisted image analysis system (Nikon NIS 
ELEMENTS BRV; Nikon Instruments, Melville, NY, USA). 
For measures of capillary density, sections were incubated 
overnight with biotinylated Bandeiraea simplicifolia Isolectin–I 
(Sigma-Aldrich Co., St Louis, MO, USA) followed by tyramide 
signal amplification enhancement (PerkinElmer Inc., Waltham, 
MA, USA). Capillaries were visualized by DAB, counted and 
expressed as the number of capillaries per mm².24
immunohistochemistry
Deparaffinized slides were treated with 3% hydrogen perox-
ide, nonspecific binding sites were blocked by incubation for 
30 minutes with goat blocking serum, followed by overnight 
incubation with anti-tumor necrosis factor-α (1:100) or anti 
CD68 (1:100).24 The visualization was performed by ABC 
kit and DAB chromogenic as peroxidase substrate, and the 
sections were counterstained with hematoxylin (all products 
from Thermo Fisher Scientific, Waltham, MA, USA). The 
percentage of immunopositive cells per total cell number in 
the same field was calculated and averaged on six sections 
for myocardial tissue. Morphometric analysis was performed 
on ten histological sections by using a Nikon Eclipse 1000 
microscope equipped with 60× objective (Nikon Instruments) 
and image analysis software (Nikon NIS Elements BR) with a 
digital camera. Measurements were performed independently 
by two blinded researchers.
apoptosis
DNA fragmentation test was performed by using the termi-
nal deoxynucleotidyl transferase mediated dUTP nick end 
labeling assay (Dead-End Colorimetric TUNEL system; 
Promega Corporation, Fitchburg, WI, USA) followed by a 
cytoplasmatic counterstain with eosin. Apoptotic index was 
calculated as previously described.25
statistics
Values are indicated as mean ± standard deviation (SD). 
Two-way ANOVA and Bonferroni post-hoc analysis were 
used to examine the significance of differences among groups 
(Graph and Prism 5.0; GraphPad Software, Inc., La Jolla, CA, 
USA). A probability value with P#0.05 was considered to 
be statistically significant.
Results
in vivo cardiotoxic effects and segment 
analysis
In order to study the cardiotoxic effects of doxorubicin 
and trastuzumab, we assessed the effects of these drugs on 
segmental and global contractility myocardial alterations. 
Groups of six mice were injected with equimolar doses of 
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trastuzumab or doxorubicin, used either as single agents or 
in combination. Echocardiography measurements were per-
formed on mouse hearts before or after 2 or 7 days treatment. 
In mice treated with doxorubicin alone, FS is reduced early 
(after 2 days) to 56.7%±2.4% vs 61.5%±1.2% (P,0.001) 
(Figure 1A). Moreover, a combinatorial treatment (doxoru-
bicin plus trastuzumab) induces a drastic reduction of FS in 
treated mice (49%±2% vs 61.5%±1.2% in sham; P,0.001). 
On the contrary, in mice treated with trastuzumab alone, 
FS decreased after 7 days of treatment (49%±3.0% vs 
60.0%±1.0%, P,0.001) (Figure 1B).
Myocardial strain has shown different results with 
respect to FS. Indeed RS was already reduced after 2 days 
in mice treated with doxorubicin alone, with trastuzumab 
alone (21.2%±8.0% vs 40.5%±4.8% sham; P,0.01), and in 
mice treated with doxorubicin plus trastuzumab. The latter 
treatment induced a drastic reduction of RS (14.6%±0.8% 
vs 41.0%±2.8% in sham, P=0.001) evaluated by speckle 
tracking. Thus, speckle tracking was able to identify the 
cardiotoxicity at a very early stage after only 2 days of treat-
ment. All these data indicate that RS is an early predictor of 
cardiac dysfunction.
Figure 1 in vivo effects of trastuzumab and doxorubicin. 
Notes: relative Fs (fractional shortening) and rs (radial strain), are reported before and after treatment of mice for 2 or 7 days with trastuzumab or doxorubicin used as 
single agents or in combination. (A) effects on Fs and rs after 2 days of treatment. (B) effects on Fs and rs after 7 days of treatment. *P,0.01; **P,0.001. P-values were 
obtained by two-way anOVa and Bonferroni post-hoc analysis and error bars are sD.
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Doxorubicin treatment induces reduction 
of capillary density, apoptosis, and fibrosis
In order to evaluate the effects of antineoplastic drugs 
in myocardial tissue, after treatment and echocardiogra-
phy examination, mice were euthanized and hearts were 
removed and processed for histological examination. We 
evaluated cardiac fibrosis after 2 days of treatment by Sirius 
red staining and apoptosis with TUNEL assay. Capillary 
density was evaluated by incubating tissue sections with 
biotinylated Bandeiraea simplicifolia Isolectin–I. As shown 
in Figure 2, doxorubicin treatment after 2 days induces a 
drastic reduction of capillary density, an increase in cardiac 
fibrosis, and increase of the density of apoptotic nuclei 
in cardiac tissue. Interestingly, the presence of fibrosis 
after only 2 days correlates with early alteration of FS. 
Cardiomyocytes showed disomogeneous cytoplasms and 
damaged disconnected myofibers. In myocardial tissue the 
distance between cells in treated mice compared to control 
mice was increased (Figure 2A).
Trastuzumab induces lV dysfunction 
detected early by rs
We have shown that treatment with trastuzumab induces 
apoptosis and a reduction of capillary density, in a fashion 
similar to doxorubicin treatment, whereas the cardiac fibrosis 
becomes important and statistically significant after 7 days 
of treatment which correlates with an important alteration 
of FS (Figure 2C). In trastuzumab-treated mice, the hearts 
showed reactive fibrosis limited to the perivascular areas. 
Moreover, we observed a few deposits of collagen “star” 
between cardiomyocytes. Interestingly, cardiac damage 
after 2 days of trastuzumab treatment was identified early 
with alteration of RS, which correlates histologically with 
an increased apoptotic index in cardiac samples (Figure 2B). 
The cytoplasm of cardiomyocytes results homogeneous, the 
nuclei have a normal appearance and no space or vacuoles 
are present (Figure 2A). These results suggest that trastu-
zumab is able to induce histological alteration in cardiac 
tissue of treated mice, thus leading to functional alterations 
detected early by RS.
Doxorubicin and trastuzumab treatment 
induces inflammatory response in cardiac 
tissue
Inflammatory response was evaluated by immunohistochem-
istry analysis with anti-TNF-α and anti-CD68 mAbs. An 
increase in inflammatory response has been observed, caused 
by trastuzumab and doxorubicin treatment, indicated by 
overexpression of TNF-α in cardiac tissue (Figure 3), which 
is an inflammatory cytokine mainly secreted by macrophages. 
Moreover, in cardiac tissue of treated mice, it is possible to 
also observe an increased presence of macrophages, as indi-
cated by positive staining with anti-CD68 mAb (Figure 4). 
The cellular infiltrates in trastuzumab treatment are more 
abundant with respect to the other treatments, and the distri-
bution of immunostaining for anti-TNF-α is uneven.
This result can be explained by the fact that during the 
apoptotic process dying cells display molecules that mark 
them for phagocytosis, thus attracting macrophages into 
cardiac tissues. The presence of an inflammatory response 
indicates early damage due to doxorubicin and trastuzumab 
treatment.
Discussion
In recent years, the use of potentially cardiotoxic antineoplas-
tic drugs has improved the survival of cancer patients, but it 
has actually created a new category of individuals at risk of 
HF. In 50% of cases, the HF is preceded, even for years, by 
asymptomatic left ventricular dysfunction (LVSD). LVSD 
itself, uncorrelated to the degree of impairment of ventricular 
function and future development of HF, increases the risk of 
death.11 When LVSD evolves in HF, the prognosis is unfavor-
able and it is comparable to that of most neoplasia: 50% die 
within 5 years from diagnosis and 10-year survival is 20%. 
Anthracyclines represent highly potent antineoplastic agents 
used against hematological and solid tumors. However, their 
use has been limited by cardiotoxic adverse effects,3 which 
may lead to congestive HF. The cardiac toxicity is directly 
related to the cumulative dose of anthracyclines received. 
However, microscopic analysis revealed myocardial damage 
already at doses as low as 180 mg/m2. The anthracycline-
related cardiotoxicity could be a problem even years after 
the last administration. Indeed, ventricular remodeling trig-
gered by myocardial damage as a consequence of a single 
low dose of anthracyclines is an ongoing process and it can 
take a long time from initial injury to clinically overt HF.20 
Trastuzumab is a humanized antibody specific for receptor 
tyrosine kinase ErbB2, overexpressed in 25% of cases of 
breast cancer. ErbB2 expression in tumors is associated with 
a poor disease-free patient survival.26 One of the most sig-
nificant forms of cardiotoxicity associated with trastuzumab 
affects the myocardium, decreasing LVEF, which can then 
progress to HF and in some cases death.11
The incidence of cardiac dysfunction is higher in patients 
who have had prior anthracycline treatment, a known trig-
ger for myocyte death, suggesting that inhibition of cardiac 
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Figure 2 effects on cardiac tissue of trastuzumab (Tra) and doxorubicin (Doxo). 
Notes: (A) representative photomicrographs of lV (left ventricular) sections from mice treated for 2 days with the indicated drugs; §fibrosis in cardiac tissue of trastuzumab-
treated mice is observed after only 7 days. (B, C) Quantification of the apoptotic nuclei and interstitial fibrosis reported as relative percentage of positive nuclei and 
Picrosirius red stained fibers after 2 days (B) and after 7 days (C). *P,0.05; **P,0.01; ***P,0.001. P-values were obtained by two-way anOVa and Bonferroni post-hoc 
analysis and error bars are sD. scale bar =50 µm.
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Figure 3 analysis of TnF-α in cardiac tissue of treated mice. 
Notes: (A) cardiac tissue of untreated mice. (B) cardiac tissue of trastuzumab-treated mice. (C) cardiac tissue of doxorubicin-treated mice. (D) Quantification of the 
TnF-α expression reported as relative percentage, after 2 days of treatment. *P,0.01. P-values were obtained by two-way anOVa and Bonferroni post-hoc analysis and 
error bars are sD. scale bar =50 µm.
Abbreviations: TnF-α, tumor necrosis factor; Tra, trastuzumab; Doxo, doxorubicin.
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Figure 4 Analysis of macrophage infiltration in cardiac tissues of treated mice by staining with anti-CD68. 
Notes: (A) cardiac tissue of untreated mice. (B) cardiac tissue of trastuzumab-treated mice. (C) cardiac tissue of doxorubicin-treated mice. (D) Quantification of the 
cD68 staining reported as relative percentage, after 2 days of treatment. *P,0.01. P-values were obtained by two-way anOVa and Bonferroni post-hoc analysis and error 
bars are sD. scale bar =50 µm.
Abbreviations: Tra, trastuzumab; Doxo, doxorubicin.
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repair mechanisms is a clinically relevant determinant of 
LVSD.27 Thus, receptor blockade by trastuzumab prevents 
this protection mechanism that is triggered by anthracycline 
treatment or other comorbidity.28
The determination of biomarkers in this setting has shown 
some limitations.29 Traditional echocardiographic index of car-
diac functionality does not identify early damage induced by 
anticancer drugs. In this work, we evaluated whether myocar-
dial strain through 2D-speckle tracking is useful to detect early 
myocardial dysfunction in a mouse model of cardiotoxicity 
due to doxorubicin and trastuzumab. A very interesting study30 
has recently indicated changes in LV diastolic function using 
2D STE immediately after administration of therapeutic doses 
of anthracycline chemotherapy. Data analysis indicates that 
the changes in diastolic function are related to reduced systolic 
function. Reduced longitudinal strain with preserved LVEF 
has been previously reported in other disease settings.31–33 A 
reduction in radial 2D strain has been reported in an animal 
model early after anthracycline therapy.34 Stoodley et al20 
reported that 2D myocardial strain imaging detects changes in 
LV systolic function immediately after anthracyclines. Two-
dimensional strain is a new simple, rapid, and reproducible 
method to measure different components of systolic strain.35,36 
This technique identified early abnormalities in patients with 
potential cardiotoxicity even though they had apparently nor-
mal LV systolic function. Clinical use of 2D strain has some 
advantages with respect to TDI strain, which can present some 
artifacts caused by myocardial translational motion, require-
ment for optimal Doppler alignment, variable reproducibility, 
and by time-consuming off-line analysis. 
In this study, we report a comparative analysis of 
doxorubicin-related and anti-ErbB2-related cardiotoxic side 
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antineoplastic-related cardiotoxicity: morphofunctional aspects
effects. Cardiotoxic effects were evaluated by traditional 
echocardiographic index and by 2D-speckle tracking (ST), to 
study global myocardial function and to perform segmental 
analysis. Moreover, histological analysis of cardiac tissues 
was performed to evaluate cardiac damage. 
Doxorubicin has been found to induce early myocardial 
contractility alteration, as shown by FS and RS reduction after 
2 days of treatment. This contractile dysfunction is related 
to high inflammatory response, death of cardiomyocytes by 
apoptosis, and fibrosis in cardiac tissues. Cellular damage is 
an ongoing process and after 7 days of treatment the inflam-
matory and apoptotic index drastically increase.
In trastuzumab-treated mice cardiotoxic effects, detected 
by conventional echocardiographic technique, appear later 
with respect to doxorubicin-treated mice. Alterations in LV 
function are evidenced later (after 7 days) with conventional 
echocardiographic technique in trastuzumab-treated mice; 
on the contrary, alterations of RS obtained by 2D-ST are 
detected earlier (after 2 days of treatment), thus preceding 
the reduction of traditional index of myocardial contractility 
(EF and FS). Furthermore, trastuzumab induces early inflam-
matory response and apoptosis in cardiac tissue, whereas 
fibrosis was observed after 7 days of treatment, when tradi-
tional contractility index also changed. Thus, with traditional 
echocardiographic technique, trastuzumab-related toxicity 
is identified after 7 days, when fibrosis is also observed in 
cardiac tissue, which is an irreversible degenerating process 
also related to aging.37 On the contrary, after only 2 days of 
treatment we observed functional (RS) and histological varia-
tions. Thus, RS alterations anticipate change of EF and FS 
and have been shown to correlate with inflammatory response 
and apoptosis, which anticipates fibrosis. 
Moreover, these data are in contrast with the clas-
sification of Type II trastuzumab-related cardiotoxicity 
proposed by Ewer and Ewer15 that indicates the absence of 
histological alterations in trastuzumab-related cardiotoxicity 
after the treatment. Guarnieri et al16 reported ultrastructural 
damage associated with reversible cardiomyopathy. 
We have already discussed the classification of antineoplastic-
related cardiotoxicity,38 and we should take into account that 
trastuzumab-related cardiotoxicity, in clinical practice, is not 
always reversible.
Clinical translation of these experimental results can 
lead to the use of RS with 2D-ST for early identification of 
antineoplastic-related cardiotoxicity in oncological patients, 
thus preventing contractile dysfunction in LV. Moreover, 
we report that trastuzumab may induce fibrosis and other 
alterations in cardiac tissue that lead to an irreversible cardiac 
dysfunction. This may be related to irreversible cardiomyo-
pathy observed in clinical practice.
We may conclude that: 1) trastuzumab induces early struc-
tural alterations, such as apoptosis and inflammation in cardiac 
tissue of treated mice in a fashion similar to doxorubicin. These 
alterations are related to early RS alteration, subsequently, other 
structural changes such as fibrosis, and the reduction of tradi-
tional cardiotoxicity indexes (FS and EF) have been reported; 
2) RS in mice can be measured with good reproducibility and 
it is significantly reduced only after 2 days of antineoplastic 
treatment, which then lead to contractile dysfunction.
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